|
Abnormality of dental color
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of the dentition
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of the gingiva
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Absence of pain sensation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acanthosis Nigricans
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, more direct evidence for abnormal tyrosine kinase receptor signalling in AN has been provided by studies of craniosynostosis and skeletal dysplasia syndromes with AN, which have identified activating mutations in fibroblast growth factor receptors.
|
12452857 |
2002 |
|
Acinar Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Acinic cell carcinomas are negative for pan-TRK, though membranous expression of TRK is common in other salivary gland neoplasms.
|
30801752 |
2019 |
|
Acral ulceration
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acute Erythroblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The tyrosine kinase receptor ErbB4 (erythroblastic leukemia viral oncogene homolog 4) plays a crucial role in numerous neurobiological processes in the developing and adult brain.
|
18854870 |
2009 |
|
Acute intermittent porphyria
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NGF expression was stronger in type 1 AIP than in CP, whereas TrkA expression in type 1 AIP was poorer than in CP.
|
28270361 |
2018 |
|
Acute interstitial pneumonia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NGF expression was stronger in type 1 AIP than in CP, whereas TrkA expression in type 1 AIP was poorer than in CP.
|
28270361 |
2018 |
|
Acute leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRK fusions have also been identified at lower frequencies across a broad range of other pediatric cancers, including undifferentiated sarcomas, gliomas, papillary thyroid cancers, spitzoid neoplasms, inflammatory myofibroblastic tumors, and acute leukemias.
|
30592640 |
2019 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, through an evaluation for TRK fusions across more than 7,000 patients with hematologic malignancies, we identified TRK fusions in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), histiocytosis, multiple myeloma, and dendritic cell neoplasms.
|
29920189 |
2018 |
|
Acute Megakaryocytic Leukemias
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TRKA expression is highest in common myeloid progenitors and is overexpressed in core binding factor and megakaryocytic leukemias, especially Down syndrome-related AML.
|
30046390 |
2018 |
|
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
|
27926778 |
2017 |
|
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
LHGDN |
siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway.
|
17671718 |
2007 |
|
Adenocarcinoma
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor that is amplified and/or overexpressed predominantly in adenocarcinomas.
|
9097992 |
1997 |
|
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
Among other tumour types, pan-TRK immunoreactivity was observed in all (100%) pleomorphic adenomas (particularly myoepithelial cell-rich, myxoid areas), 15 (83%) polymorphous adenocarcinomas, and four (20%) low-grade mucoepidermoid carcinomas, all with predominantly membranous/cytoplasmic immunoreactivity; only six cases showed focal (<10%) nuclear staining.
|
30801752 |
2019 |
|
Adenocarcinoma
|
0.060 |
AlteredExpression
|
group |
LHGDN |
The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas.
|
16862449 |
2007 |
|
Adenocarcinoma
|
0.060 |
Biomarker
|
group |
BEFREE |
Of these cases, 12 were positive for NTRK1 fusion, including 10 cases of adenocarcinoma (0.073%), 1 primary sarcomatoid carcinoma, and 1 with an unknown histologic classification.
|
31761448 |
2019 |
|
Adenocarcinoma of large intestine
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Adenocarcinoma of lung (disorder)
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In the remaining cohort of lung AD without these known drivers, 273 cancer-related genes were altered in at least 0.1% of cases, including STK11 (21%), NF1 (13%), MYC (9.8%), RICTOR (6.4%), PIK3CA (5.4%), CDK4 (4.3%), CCND1 (4.0%), BRCA2 (2.5%), NRAS (2.3%), BRCA1 (1.7%), MAP2K1 (1.2%), HRAS (0.7%), NTRK1 (0.7%), and NTRK3 (0.2%).
|
27151654 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Method:</b> BPI-9016M, a c-Met tyrosine kinase receptor inhibitor, was used to treat patient-derived xenografts (PDX) from lung adenocarcinoma in NOD/SCID mice.
|
30613269 |
2018 |
|
Adenoid Cystic Carcinoma
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
Nerve growth factor and tyrosine kinase A in human salivary adenoid cystic carcinoma: expression patterns and effects on in vitro invasive behavior.
|
16546643 |
2006 |
|
Adenoma
|
0.020 |
Biomarker
|
group |
BEFREE |
In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75<sup>NTR</sup>, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62).
|
29037860 |
2018 |
|
Adenoma
|
0.020 |
Biomarker
|
group |
BEFREE |
The frequency, if we consider exclusively the papillary carcinomas, is in both cases 12%; (b) show that the TRK oncogene plays a role in the development of a minority of radiation-associated papillary thyroid carcinomas but not in adenomas; and (c) confirm that RET/PTC rearrangements are the major genetic alteration associated with ionizing radiation-induced thyroid tumorigenesis.
|
10646882 |
2000 |